EPISODE · Aug 22, 2022 · 10 MIN
Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast
from Stock Day Media · host Stock Day Media
The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (TRVI) (“the Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF). President and CEO of the Company, Jennifer Good, joined Stock Day host Sever Copley. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
What this episode covers
The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (TRVI) (“the Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF). President and CEO of the Company, Jennifer Good, joined Stock Day host Sever Copley. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
NOW PLAYING
Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.